Chardan Capital Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a price target of $60.
August 08, 2023 | 5:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arrowhead Pharma's stock rating has been reiterated as 'Buy' by Chardan Capital, with a maintained price target of $60.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Arrowhead Pharma. The maintained price target of $60 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100